Option chain shows key data for InnoCan Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for InnoCan Pharma.

InnoCan Pharma (OTC:INNPF) Stock, Option Chain

Summit Hotel Properties

InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.

TWIC

Cannabis

Earnings

Government

Regulations

AAWH

AYRWF

CSE:MRMD

GRAM

Grindrod Shipping Holdings Ltd Ordinary Shares

GRIN

GRUSF

IIPR

IMCC

INNO

INNPF

JSDA

LIEN

MEDIF

MRMD

ROMJF

SHF Holdings, Inc. - Class A Common Stock

SHFS

TLLTF

WEED

This week in cannabis: major mergers, innovative launches, key regulatory updates &amp; leadership changes drive industry transformation.

This Week In Cannabis: Trump Policy Updates, Corporate Moves, Regulatory Shifts And Product Innovations

cannabis, stock market, trading, earnings Business,Cannabis,Leaves,Marijuana,Stock,Exchange,Market,Or,Trading,Analysis

News

Innocan Pharma reports 174% YoY revenue growth in Q3 2024, driven by innovation in cannabinoids and strong sales from BI Sky Global Ltd.

Cannabinoid Leader Innocan Pharma&#39;s Q3: 174% YoY Revenue Growth

cannabis money, cannabis earnings, marjijuana money,

AMZN

CSE:INNO

Innocan Pharma&#39;s Q1 2024 revenue surged 334% to $6.8M, driven by strong sales growth from BI Sky Global. Read about financial performance.

CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark

Summit Hotel Properties, Inc. 5.875% Series F Cumulative Redeemable Preferred Stock, $0.01 par value per share

Summit Hotel Properties Inc

INNOCAN PHARMA CORP. by Innocan Pharma Corp.

InnoCan Pharma Corp

Small Cap

Press Releases

Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone

Innocan Pharma's Liposomal CBD Injection Shows Breakthrough Pain Relief in Elderly Donkey with Osteoarthritis

Innocan Pharma Announces Private Placement Offering of a Debenture Unit to its Largest Shareholder, Tamar Innovest

Innocan Pharma Announces Closing of Debenture Unit Offering to its Largest Shareholder, Tamar Innovest Limited

Innocan Pharma Reports Full Year 2024 Results with Revenues more than Doubling to US $29.4 million

Innocan Pharma Broadens Intellectual Property Coverage for its Liposomal CBD Injection Across Asia and Announces Private Placement of Units

Offerings

Innocan Pharma Announces Closing of Private Placement

Innocan Pharma First Granted Patent in Mexico for its Topical Pain Relief

Innocan Pharma Announces First Quarter 2025 Financial Results with Continued Strong Revenue Growth and Provides Corporate Update

Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach

InnoCan Pharma

Comments

InnoCan Pharma

InnoCan Pharma (INNPF) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell